ASX:OCC

Orthocell Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume669,530 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive OCC News and Ratings via Email

Sign-up to receive the latest news and ratings for Orthocell and its competitors with MarketBeat's FREE daily newsletter.


About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. Orthocell Limited was founded in 2006 and is based in Murdoch, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.32 out of 5 stars

Analyst Opinion: 0.0Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Orthocell (ASX:OCC) Frequently Asked Questions

What stocks does MarketBeat like better than Orthocell?

Wall Street analysts have given Orthocell a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Orthocell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Orthocell's key executives?

Orthocell's management team includes the following people:
  • Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D., Exec. Chairman (Age 51, Pay $150k)
  • Mr. Paul Anderson, CEO, MD & Exec. Director (Age 55, Pay $495.55k)
  • Ms. Leslie Wise J.D., Exec. Director
  • Ms. Nicole Jane Telford, Chief Financial Officer
  • Mr. Alex McHenry, Chief Operating Officer
  • Prof. Ming Hao Zheng, Chief Scientific Officer and Member of Medical & Scientific Advisory Board
  • Mr. Simon Lee Robertson B.Bus, CA, M Appl. Fin., Company Sec. (Age 61)

Who are some of Orthocell's key competitors?

What other stocks do shareholders of Orthocell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthocell investors own include Plug Power (PLUG), Viralytics (VRACY), Genetic Technologies (GTG) and GP Strategies (GPX).

What is Orthocell's stock symbol?

Orthocell trades on the ASX under the ticker symbol "OCC."

How much money does Orthocell make?

Orthocell has a market capitalization of $0.00 and generates $797,629.00 in revenue each year.

What is Orthocell's official website?

The official website for Orthocell is www.orthocell.com.au.

How can I contact Orthocell?

The company can be reached via phone at 61 8 9360 2888.


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.